{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:58:46Z","timestamp":1792511926703,"version":"4.5.0"},"reference-count":197,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100015691","name":"Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01AI101047"],"award-info":[{"award-number":["R01AI101047"]}],"id":[{"id":"10.13039\/100015691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s40259-026-00791-z","type":"journal-article","created":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T08:22:45Z","timestamp":1781511765000},"page":"581-597","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["mRNA Vaccines for Influenza: Hope for a Universal Vaccine?"],"prefix":"10.1007","volume":"40","author":[{"given":"Priscilla","family":"Omotara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wandi","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1561-4318","authenticated-orcid":false,"given":"Bao-Zhong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,15]]},"reference":[{"issue":"8","key":"791_CR1","doi-asserted-by":"publisher","first-page":"4638","DOI":"10.1002\/jmv.26990","volume":"93","author":"M Javanian","year":"2021","unstructured":"Javanian M, Barary M, Ghebrehewet S, Koppolu V, Vasigala V, Ebrahimpour S. A brief review of influenza virus infection. J Med Virol. 2021;93(8):4638\u201346. https:\/\/doi.org\/10.1002\/jmv.26990.","journal-title":"J Med Virol"},{"key":"791_CR2","doi-asserted-by":"publisher","DOI":"10.1128\/cmr.00040-22","author":"R Kumari","year":"2023","unstructured":"Kumari R, Sharma SD, Kumar A, Ende Z, Mishina M, Wang Y, et al. Antiviral approaches against influenza virus. Clin Microbiol Rev. 2023. https:\/\/doi.org\/10.1128\/cmr.00040-22.","journal-title":"Clin Microbiol Rev"},{"issue":"9","key":"791_CR3","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.3390\/vaccines9091032","volume":"9","author":"RF Nuwarda","year":"2021","unstructured":"Nuwarda RF, Alharbi AA, Kayser V. An overview of influenza viruses and vaccines. Vaccines. 2021;9(9):1032. https:\/\/doi.org\/10.3390\/vaccines9091032.","journal-title":"Vaccines"},{"issue":"3","key":"791_CR4","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1159\/000538382","volume":"69","author":"G Pavia","year":"2024","unstructured":"Pavia G, Scarpa F, Ciccozzi A, Romano C, Branda F, Quirino A, et al. Changing and evolution of influenza virus: is it a trivial flu? Chemotherapy. 2024;69(3):185\u201393. https:\/\/doi.org\/10.1159\/000538382.","journal-title":"Chemotherapy"},{"issue":"5","key":"791_CR5","doi-asserted-by":"publisher","first-page":"714","DOI":"10.3390\/vaccines10050714","volume":"10","author":"CM Trombetta","year":"2022","unstructured":"Trombetta CM, Kistner O, Montomoli E, Viviani S, Marchi S. Influenza viruses and vaccines: the role of vaccine effectiveness studies for evaluation of the benefits of influenza vaccines. Vaccines. 2022;10(5):714. https:\/\/doi.org\/10.3390\/vaccines10050714.","journal-title":"Vaccines"},{"issue":"1","key":"791_CR6","doi-asserted-by":"publisher","first-page":"2223057","DOI":"10.1080\/21505594.2023.2223057","volume":"14","author":"Y Liang","year":"2023","unstructured":"Liang Y. Pathogenicity and virulence of influenza. Virulence. 2023;14(1):2223057. https:\/\/doi.org\/10.1080\/21505594.2023.2223057.","journal-title":"Virulence."},{"issue":"3","key":"791_CR7","doi-asserted-by":"publisher","first-page":"2407241","DOI":"10.1002\/advs.202407241","volume":"12","author":"YD Tang","year":"2025","unstructured":"Tang YD, Li Y, Cai XH, Yin X. Viral live-attenuated vaccines (LAVs): past and future directions. Adv Sci. 2025;12(3):2407241. https:\/\/doi.org\/10.1002\/advs.202407241.","journal-title":"Adv Sci"},{"key":"791_CR8","unstructured":"CDC. Live attenuated influenza vaccine [LAIV] (the nasal spray flu vaccine). 2022. https:\/\/www.cdc.gov\/flu\/vaccine-types\/nasalspray.html. Accessed 14 Nov 2025."},{"issue":"9","key":"791_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2024.104125","volume":"29","author":"CH Jones","year":"2024","unstructured":"Jones CH, Hauguel T, Beitelshees M, Davitt M, Welch V, Lindert K, et al. Deciphering immune responses: a comparative analysis of influenza vaccination platforms. Drug Discov Today. 2024;29(9):104125. https:\/\/doi.org\/10.1016\/j.drudis.2024.104125.","journal-title":"Drug Discov Today"},{"issue":"6","key":"791_CR10","doi-asserted-by":"publisher","first-page":"971","DOI":"10.3390\/v13060971","volume":"13","author":"T Sekiya","year":"2021","unstructured":"Sekiya T, Ohno M, Nomura N, Handabile C, Shingai M, Jackson DC, et al. Selecting and using the appropriate influenza vaccine for each individual. Viruses. 2021;13(6):971. https:\/\/doi.org\/10.3390\/v13060971.","journal-title":"Viruses"},{"issue":"8","key":"791_CR11","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.3390\/v14081684","volume":"14","author":"W-C Wang","year":"2022","unstructured":"Wang W-C, Sayedahmed EE, Sambhara S, Mittal SK. Progress towards the development of a universal influenza vaccine. Viruses. 2022;14(8):1684. https:\/\/doi.org\/10.3390\/v14081684.","journal-title":"Viruses"},{"key":"791_CR12","doi-asserted-by":"publisher","first-page":"251513552090812","DOI":"10.1177\/2515135520908121","volume":"8","author":"S Rajaram","year":"2020","unstructured":"Rajaram S, Boikos C, Gelone DK, Gandhi A. Influenza vaccines: the potential benefits of cell-culture isolation and manufacturing. Ther Adv Vaccines Immunother. 2020;8:251513552090812. https:\/\/doi.org\/10.1177\/2515135520908121.","journal-title":"Ther Adv Vaccines Immunother."},{"issue":"2","key":"791_CR13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0229279","volume":"15","author":"NP Klein","year":"2020","unstructured":"Klein NP, Fireman B, Goddard K, Zerbo O, Asher J, Zhou J, et al. Vaccine effectiveness of cell-culture relative to egg-based inactivated influenza vaccine during the 2017\u201318 influenza season. PLoS ONE. 2020;15(2):e0229279. https:\/\/doi.org\/10.1371\/journal.pone.0229279.","journal-title":"PLoS ONE"},{"key":"791_CR14","doi-asserted-by":"publisher","first-page":"878943","DOI":"10.3389\/fimmu.2022.878943","volume":"13","author":"MB Carascal","year":"2022","unstructured":"Carascal MB, Pavon RDN, Rivera WL. Recent progress in recombinant influenza vaccine development toward heterosubtypic immune response. Front Immunol. 2022;13:878943. https:\/\/doi.org\/10.3389\/fimmu.2022.878943.","journal-title":"Front Immunol"},{"issue":"26","key":"791_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2024.126408","volume":"42","author":"J Taaffe","year":"2024","unstructured":"Taaffe J, Ostrowsky JT, Mott J, Goldin S, Friede M, Gsell P, et al. Advancing influenza vaccines: a review of next-generation candidates and their potential for global health impact. Vaccine. 2024;42(26):126408. https:\/\/doi.org\/10.1016\/j.vaccine.2024.126408.","journal-title":"Vaccine"},{"issue":"6","key":"791_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2025.107617","volume":"66","author":"H Mabuchi","year":"2025","unstructured":"Mabuchi H, Kawano T, Gobaru R, Yoshinaga K, Ueo A, Hashimoto K, et al. Evaluation of the effect of two adjuvants coadministered with nasal recombinant hemagglutinin influenza vaccine on immune cells in mice. Int J Antimicrob Agents. 2025;66(6):107617. https:\/\/doi.org\/10.1016\/j.ijantimicag.2025.107617.","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"791_CR17","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s12929-020-0626-6","volume":"27","author":"J-R Chen","year":"2020","unstructured":"Chen J-R, Liu Y-M, Tseng Y-C, Ma C. Better influenza vaccines: an industry perspective. J Biomed Sci. 2020;27(1):33. https:\/\/doi.org\/10.1186\/s12929-020-0626-6.","journal-title":"J Biomed Sci"},{"issue":"1","key":"791_CR18","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1146\/annurev-virology-010320-044746","volume":"7","author":"S Gouma","year":"2020","unstructured":"Gouma S, Anderson EM, Hensley SE. Challenges of making effective influenza vaccines. Annu Rev Virol. 2020;7(1):495\u2013512. https:\/\/doi.org\/10.1146\/annurev-virology-010320-044746.","journal-title":"Annu Rev Virol."},{"key":"791_CR19","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.jconrel.2021.08.029","volume":"338","author":"AK Blakney","year":"2021","unstructured":"Blakney AK, McKay PF, Hu K, Samnuan K, Jain N, Brown A, et al. Polymeric and lipid nanoparticles for delivery of self-amplifying RNA vaccines. J Controlled Release. 2021;338:201\u201310. https:\/\/doi.org\/10.1016\/j.jconrel.2021.08.029.","journal-title":"J Controlled Release."},{"key":"791_CR20","doi-asserted-by":"publisher","first-page":"906457","DOI":"10.3389\/fimmu.2022.906457","volume":"13","author":"Y Wu","year":"2022","unstructured":"Wu Y, Zhang H, Meng L, Li F, Yu C. Comparison of immune responses elicited by SARS-CoV-2 mRNA and recombinant protein vaccine candidates. Front Immunol. 2022;13:906457. https:\/\/doi.org\/10.3389\/fimmu.2022.906457.","journal-title":"Front Immunol"},{"issue":"17","key":"791_CR21","doi-asserted-by":"publisher","DOI":"10.1172\/jci194586","volume":"135","author":"C Subramani","year":"2025","unstructured":"Subramani C, Meyer MN, Hyde MA, Comeaux ME, Hao H, Crowe JE Jr, et al. Marburg virus glycoprotein mRNA vaccine is more protective than a virus-like particle-forming mRNA vaccine. J Clin Investig. 2025;135(17):e194586. https:\/\/doi.org\/10.1172\/jci194586.","journal-title":"J Clin Investig"},{"issue":"27","key":"791_CR22","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/nejmoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603\u201315. https:\/\/doi.org\/10.1056\/nejmoa2034577.","journal-title":"N Engl J Med"},{"issue":"15","key":"791_CR23","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1056\/nejmoa2101765","volume":"384","author":"N Dagan","year":"2021","unstructured":"Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, et al. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. N Engl J Med. 2021;384(15):1412\u201323. https:\/\/doi.org\/10.1056\/nejmoa2101765.","journal-title":"N Engl J Med"},{"key":"791_CR24","doi-asserted-by":"publisher","first-page":"107237","DOI":"10.1016\/j.ypmed.2022.107237","volume":"163","author":"P Chico-S\u00e1nchez","year":"2022","unstructured":"Chico-S\u00e1nchez P, Gras-Valent\u00ed P, Algado-Sell\u00e9s N, Jim\u00e9nez-Sep\u00falveda N, Vanaclocha H, Peir\u00f3 S, et al. The effectiveness of mRNA vaccines to prevent SARS-CoV-2 infection and hospitalisation for COVID-19 according to the time elapsed since their administration in health professionals in the Valencian Autonomous Community (Spain). Prev Med. 2022;163:107237. https:\/\/doi.org\/10.1016\/j.ypmed.2022.107237.","journal-title":"Prev Med"},{"key":"791_CR25","unstructured":"FDA. SPIKEVAX. 2025. https:\/\/www.fda.gov\/vaccines-blood-biologics\/spikevax. Accessed 14 Nov 2025."},{"key":"791_CR26","unstructured":"FDA. MNEXSPIKE. 2025. https:\/\/www.fda.gov\/vaccines-blood-biologics\/mnexspike. Accessed 14 Nov 2025."},{"key":"791_CR27","unstructured":"FDA. COMIRNATY. 2025. https:\/\/www.fda.gov\/vaccines-blood-biologics\/comirnaty. Accessed 14 Nov 2025."},{"key":"791_CR28","unstructured":"FDA. MRESVIA. 2025. https:\/\/www.fda.gov\/vaccines-blood-biologics\/vaccines\/mresvia. Accessed 14 Nov 2025."},{"issue":"3","key":"791_CR29","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1093\/infdis\/jiy103","volume":"218","author":"EJ Erbelding","year":"2018","unstructured":"Erbelding EJ, Post DJ, Stemmy EJ, Roberts PC, Augustine AD, Ferguson S, et al. A universal influenza vaccine: the strategic plan for the national institute of allergy and infectious diseases. J Infect Dis. 2018;218(3):347\u201354. https:\/\/doi.org\/10.1093\/infdis\/jiy103.","journal-title":"J Infect Dis"},{"key":"791_CR30","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1093\/jpids\/piz086","volume":"9","author":"J Treanor","year":"2020","unstructured":"Treanor J. History of live, attenuated influenza vaccine. J Pediatr Infect Dis Soc. 2020;9:S3\u20139. https:\/\/doi.org\/10.1093\/jpids\/piz086.","journal-title":"J Pediatr Infect Dis Soc"},{"key":"791_CR31","doi-asserted-by":"publisher","first-page":"711997","DOI":"10.3389\/fimmu.2021.711997","volume":"12","author":"J Chen","year":"2021","unstructured":"Chen J, Wang J, Zhang J, Ly H. Advances in development and application of influenza vaccines. Front Immunol. 2021;12:711997. https:\/\/doi.org\/10.3389\/fimmu.2021.711997.","journal-title":"Front Immunol"},{"key":"791_CR32","doi-asserted-by":"publisher","first-page":"127393","DOI":"10.1016\/j.vaccine.2025.127393","volume":"62","author":"M Ashraf","year":"2025","unstructured":"Ashraf M, Stein AN, Youhanna J, Rockman S, McMahon M, McGovern I, et al. The impact of egg adaptation and immune imprinting on influenza vaccine effectiveness. Vaccine. 2025;62:127393. https:\/\/doi.org\/10.1016\/j.vaccine.2025.127393.","journal-title":"Vaccine"},{"issue":"11","key":"791_CR33","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.3390\/vaccines10111796","volume":"10","author":"L Li","year":"2022","unstructured":"Li L, Shi N, Xu N, Wang H, Zhao H, Xu H, et al. Safety and viral shedding of live attenuated influenza vaccine (LAIV) in Chinese healthy juveniles and adults: a phase I randomized, double-blind, placebo-controlled study. Vaccines. 2022;10(11):1796. https:\/\/doi.org\/10.3390\/vaccines10111796.","journal-title":"Vaccines"},{"issue":"1","key":"791_CR34","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/s41541-025-01255-1","volume":"10","author":"Q Zhang","year":"2025","unstructured":"Zhang Q, Cheng J, Hou J, Su Y, Li L, Tong L, et al. Synthetic biology-inspired development of live attenuated influenza vaccines. npj Vaccines. 2025;10(1):204. https:\/\/doi.org\/10.1038\/s41541-025-01255-1.","journal-title":"npj Vaccines"},{"issue":"6","key":"791_CR35","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.2074","volume":"29","author":"A Sabbaghi","year":"2019","unstructured":"Sabbaghi A, Miri SM, Keshavarz M, Zargar M, Ghaemi A. Inactivation methods for whole influenza vaccine production. Rev Med Virol. 2019;29(6):e2074. https:\/\/doi.org\/10.1002\/rmv.2074.","journal-title":"Rev Med Virol"},{"issue":"11","key":"791_CR36","doi-asserted-by":"publisher","first-page":"2525","DOI":"10.1002\/cjce.24197","volume":"99","author":"CAT Silva","year":"2021","unstructured":"Silva CAT, Kamen AA, Henry O. Recent advances and current challenges in process intensification of cell culture-based influenza virus vaccine manufacturing. Can J Chem Eng. 2021;99(11):2525\u201335. https:\/\/doi.org\/10.1002\/cjce.24197.","journal-title":"Can J Chem Eng"},{"issue":"10","key":"791_CR37","doi-asserted-by":"publisher","first-page":"3652","DOI":"10.1080\/21645515.2021.1932218","volume":"17","author":"Y Liang","year":"2021","unstructured":"Liang Y, Jing-Xia G, Ma L, Ni L, Chaolie R, Zhou J, et al. Immunogenicity and safety levels of inactivated quadrivalent influenza vaccine in healthy adults via meta-analysis. Hum Vaccin Immunother. 2021;17(10):3652\u201361. https:\/\/doi.org\/10.1080\/21645515.2021.1932218.","journal-title":"Hum Vaccin Immunother"},{"issue":"1","key":"791_CR38","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41541-021-00403-7","volume":"6","author":"AB Arunachalam","year":"2021","unstructured":"Arunachalam AB, Post P, Rudin D. Unique features of a recombinant haemagglutinin influenza vaccine that influence vaccine performance. npj Vaccines. 2021;6(1):144. https:\/\/doi.org\/10.1038\/s41541-021-00403-7.","journal-title":"npj Vaccines"},{"key":"791_CR39","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.692151","volume":"12","author":"JE Hernandez-Davies","year":"2021","unstructured":"Hernandez-Davies JE, Felgner J, Strohmeier S, Pone EJ, Jain A, Jan S, et al. Administration of multivalent influenza virus recombinant hemagglutinin vaccine in combination-adjuvant elicits broad reactivity beyond the vaccine components. Front Immunol. 2021;12:692151. https:\/\/doi.org\/10.3389\/fimmu.2021.692151.","journal-title":"Front Immunol"},{"issue":"1","key":"791_CR40","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s43141-023-00581-y","volume":"21","author":"D Gupta","year":"2023","unstructured":"Gupta D, Mohan S. Influenza vaccine: a review on current scenario and future prospects. J Genet Eng Biotechnol. 2023;21(1):154. https:\/\/doi.org\/10.1186\/s43141-023-00581-y.","journal-title":"J Genet Eng Biotechnol"},{"key":"791_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2021.101262","volume":"44","author":"KM Pollock","year":"2022","unstructured":"Pollock KM, Cheeseman HM, Szubert AJ, Libri V, Boffito M, Owen D, et al. Safety and immunogenicity of a self-amplifying RNA vaccine against COVID-19: COVAC1, a phase I, dose-ranging trial. eClinicalMedicine. 2022;44:101262. https:\/\/doi.org\/10.1016\/j.eclinm.2021.101262.","journal-title":"eClinicalMedicine"},{"issue":"16","key":"791_CR42","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1016\/j.vaccine.2021.03.038","volume":"39","author":"SS Rosa","year":"2021","unstructured":"Rosa SS, Prazeres DMF, Azevedo AM, Marques MPC. mRNA vaccines manufacturing: challenges and bottlenecks. Vaccine. 2021;39(16):2190\u2013200. https:\/\/doi.org\/10.1016\/j.vaccine.2021.03.038.","journal-title":"Vaccine"},{"issue":"1","key":"791_CR43","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s12985-025-02645-6","volume":"22","author":"KY Leong","year":"2025","unstructured":"Leong KY, Tham SK, Poh CL. Revolutionizing immunization: a comprehensive review of mRNA vaccine technology and applications. Virol J. 2025;22(1):71. https:\/\/doi.org\/10.1186\/s12985-025-02645-6.","journal-title":"Virol J."},{"issue":"7","key":"791_CR44","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1038\/s12276-023-00999-x","volume":"55","author":"J Lee","year":"2023","unstructured":"Lee J, Woodruff MC, Kim EH, Nam J-H. Knife\u2019s edge: balancing immunogenicity and reactogenicity in mRNA vaccines. Exp Mol Med. 2023;55(7):1305\u201313. https:\/\/doi.org\/10.1038\/s12276-023-00999-x.","journal-title":"Exp Mol Med"},{"issue":"15","key":"791_CR45","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1001\/jama.2021.3645","volume":"325","author":"KE Stephenson","year":"2021","unstructured":"Stephenson KE, Le Gars M, Sadoff J, De Groot AM, Heerwegh D, Truyers C, et al. Immunogenicity of the Ad26.COV2.S vaccine for COVID-19. JAMA. 2021;325(15):1535. https:\/\/doi.org\/10.1001\/jama.2021.3645.","journal-title":"JAMA"},{"issue":"7","key":"791_CR46","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.3390\/vaccines11071142","volume":"11","author":"Y Liu","year":"2023","unstructured":"Liu Y, Li Y, Hu Q. Advances in saRNA vaccine research against emerging\/re-emerging viruses. Vaccines. 2023;11(7):1142. https:\/\/doi.org\/10.3390\/vaccines11071142.","journal-title":"Vaccines"},{"issue":"1","key":"791_CR47","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41541-025-01135-8","volume":"10","author":"JA Wojcechowskyj","year":"2025","unstructured":"Wojcechowskyj JA, Jong RM, M\u00e4ger I, Flach B, Munson PV, Mukherjee PP, et al. Controlling reactogenicity while preserving immunogenicity from a self-amplifying RNA vaccine by modulating nucleocytoplasmic transport. npj Vaccines. 2025;10(1):85. https:\/\/doi.org\/10.1038\/s41541-025-01135-8.","journal-title":"npj Vaccines"},{"key":"791_CR48","doi-asserted-by":"publisher","first-page":"126883","DOI":"10.1016\/j.vaccine.2025.126883","volume":"51","author":"C Chang","year":"2025","unstructured":"Chang C, Patel H, Ferrari A, Scalzo T, Petkov D, Xu H, et al. Sa-mRNA influenza vaccine raises a higher and more durable immune response than mRNA vaccine in preclinical models. Vaccine. 2025;51:126883. https:\/\/doi.org\/10.1016\/j.vaccine.2025.126883.","journal-title":"Vaccine"},{"issue":"8","key":"791_CR49","doi-asserted-by":"publisher","first-page":"692","DOI":"10.3390\/pathogens13080692","volume":"13","author":"Z Zhang","year":"2024","unstructured":"Zhang Z, Fu Y, Ju X, Zhang F, Zhang P, He M. Advances in engineering circular rna vaccines. Pathogens. 2024;13(8):692. https:\/\/doi.org\/10.3390\/pathogens13080692.","journal-title":"Pathogens"},{"issue":"4","key":"791_CR50","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0297833","volume":"19","author":"ZB Reneer","year":"2024","unstructured":"Reneer ZB, Bergeron HC, Reynolds S, Thornhill-Wadolowski E, Feng L, Bugno M, et al. mRNA vaccines encoding influenza virus hemagglutinin (HA) elicits immunity in mice from influenza A virus challenge. PLoS ONE. 2024;19(4):e0297833. https:\/\/doi.org\/10.1371\/journal.pone.0297833.","journal-title":"PLoS ONE"},{"issue":"12","key":"791_CR51","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.3390\/vaccines12121382","volume":"12","author":"Z Cheng","year":"2024","unstructured":"Cheng Z, Ma J, Zhao C. Advantages of broad-spectrum influenza mRNA vaccines and their impact on pulmonary influenza. Vaccines. 2024;12(12):1382. https:\/\/doi.org\/10.3390\/vaccines12121382.","journal-title":"Vaccines"},{"issue":"1","key":"791_CR52","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/s41541-023-00752-5","volume":"8","author":"CM Kackos","year":"2023","unstructured":"Kackos CM, Debeauchamp J, Davitt CJH, Lonzaric J, Sealy RE, Hurwitz JL, et al. Seasonal quadrivalent mRNA vaccine prevents and mitigates influenza infection. npj Vaccines. 2023;8(1):157. https:\/\/doi.org\/10.1038\/s41541-023-00752-5.","journal-title":"npj Vaccines."},{"issue":"1","key":"791_CR53","doi-asserted-by":"publisher","first-page":"e113","DOI":"10.1093\/infdis\/jiae329","volume":"231","author":"J Ananworanich","year":"2025","unstructured":"Ananworanich J, Lee IT, Ensz D, Carmona L, Schaefers K, Avanesov A, et al. Safety and immunogenicity of mRNA-1010, an investigational seasonal influenza vaccine, in healthy adults: final results from a phase 1\/2 randomized trial. J Infect Dis. 2025;231(1):e113\u201322. https:\/\/doi.org\/10.1093\/infdis\/jiae329.","journal-title":"J Infect Dis"},{"issue":"1","key":"791_CR54","doi-asserted-by":"publisher","first-page":"3631","DOI":"10.1038\/s41467-023-39376-7","volume":"14","author":"IT Lee","year":"2023","unstructured":"Lee IT, Nachbagauer R, Ensz D, Schwartz H, Carmona L, Schaefers K, et al. Safety and immunogenicity of a phase 1\/2 randomized clinical trial of a quadrivalent, mRNA-based seasonal influenza vaccine (mRNA-1010) in healthy adults: interim analysis. Nat Commun. 2023;14(1):3631. https:\/\/doi.org\/10.1038\/s41467-023-39376-7.","journal-title":"Nat Commun"},{"issue":"1","key":"791_CR55","doi-asserted-by":"publisher","first-page":"2484088","DOI":"10.1080\/21645515.2025.2484088","volume":"21","author":"B Kandinov","year":"2025","unstructured":"Kandinov B, Soens M, Huang W, Llapur C, Ensz D, Essink B, et al. An mRNA-based seasonal influenza vaccine in adults: results of two phase 3 randomized clinical trials and correlate of protection analysis of hemagglutination inhibition titers. Hum Vaccin Immunother. 2025;21(1):2484088. https:\/\/doi.org\/10.1080\/21645515.2025.2484088.","journal-title":"Hum Vaccin Immunother"},{"key":"791_CR56","doi-asserted-by":"publisher","first-page":"126847","DOI":"10.1016\/j.vaccine.2025.126847","volume":"50","author":"M Soens","year":"2025","unstructured":"Soens M, Ananworanich J, Hicks B, Lucas KJ, Cardona J, Sher L, et al. A phase 3 randomized safety and immunogenicity trial of mRNA-1010 seasonal influenza vaccine in adults. Vaccine. 2025;50:126847. https:\/\/doi.org\/10.1016\/j.vaccine.2025.126847.","journal-title":"Vaccine"},{"issue":"Supplement_2","key":"791_CR57","doi-asserted-by":"publisher","first-page":"ofad500.1473","DOI":"10.1093\/ofid\/ofad500.1473","volume":"10","author":"M Soens","year":"2023","unstructured":"Soens M, Kandinov B, Ramirez-Schrempp D, Vakil J, Pucci A, Huang W, et al. 1639. A review of clinical safety, reactogenicity, and immunogenicity of an mRNA-based seasonal influenza vaccine (mRNA-1010) in adults. Open Forum Infect Dis. 2023;10(Supplement_2):ofad500.1473. https:\/\/doi.org\/10.1093\/ofid\/ofad500.1473.","journal-title":"Open Forum Infect Dis"},{"issue":"6622","key":"791_CR58","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1126\/science.abm0271","volume":"378","author":"CP Arevalo","year":"2022","unstructured":"Arevalo CP, Bolton MJ, Le Sage V, Ye N, Furey C, Muramatsu H, et al. A multivalent nucleoside-modified mRNA vaccine against all known influenza virus subtypes. Science. 2022;378(6622):899\u2013904. https:\/\/doi.org\/10.1126\/science.abm0271.","journal-title":"Science"},{"issue":"1","key":"791_CR59","doi-asserted-by":"publisher","first-page":"4677","DOI":"10.1038\/s41467-022-32149-8","volume":"13","author":"N Pardi","year":"2022","unstructured":"Pardi N, Carre\u00f1o JM, O\u2019Dell G, Tan J, Bajusz C, Muramatsu H, et al. Development of a pentavalent broadly protective nucleoside-modified mRNA vaccine against influenza B viruses. Nat Commun. 2022;13(1):4677. https:\/\/doi.org\/10.1038\/s41467-022-32149-8.","journal-title":"Nat Commun"},{"issue":"9","key":"791_CR60","doi-asserted-by":"publisher","first-page":"e00668-24","DOI":"10.1128\/mbio.00668-24","volume":"15","author":"Y Wang","year":"2024","unstructured":"Wang Y, Ma Q, Li M, Mai Q, Ma L, Zhang H, et al. A decavalent composite mRNA vaccine against both influenza and COVID-19. MBio. 2024;15(9):e00668-24. https:\/\/doi.org\/10.1128\/mbio.00668-24.","journal-title":"MBio"},{"issue":"8","key":"791_CR61","doi-asserted-by":"publisher","DOI":"10.1016\/s2666-5247(24)00066-1","volume":"5","author":"S Caini","year":"2024","unstructured":"Caini S, Meijer A, Nunes MC, Henaff L, Zounon M, Boudewijns B, et al. Probable extinction of influenza B\/Yamagata and its public health implications: a systematic literature review and assessment of global surveillance databases. Lancet Microbe. 2024;5(8):100851. https:\/\/doi.org\/10.1016\/s2666-5247(24)00066-1.","journal-title":"Lancet Microbe."},{"key":"791_CR62","unstructured":"WHO. Recommended composition of influenza virus vaccines for use in the 2024\u20132025 northern hemisphere influenza season. 2024. https:\/\/www.who.int\/publications\/m\/item\/recommended-composition-of-influenza-virus-vaccines-for-use-in-the-2024-2025-northern-hemisphere-influenza-season. Accessed 14 Nov 2025."},{"issue":"12","key":"791_CR63","doi-asserted-by":"publisher","first-page":"ofad577","DOI":"10.1093\/ofid\/ofad577","volume":"10","author":"A Fall","year":"2023","unstructured":"Fall A, Han L, Yunker M, Gong Y-N, Li T-J, Norton JM, et al. Evolution of influenza A(H3N2) viruses in 2 consecutive seasons of genomic surveillance, 2021\u20132023. Open Forum Infect Dis. 2023;10(12):ofad577. https:\/\/doi.org\/10.1093\/ofid\/ofad577.","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"791_CR64","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/s1473-3099(24)00493-6","volume":"25","author":"D Hsu","year":"2025","unstructured":"Hsu D, Jayaraman A, Pucci A, Joshi R, Mancini K, Chen HL, et al. Safety and immunogenicity of mRNA-based seasonal influenza vaccines formulated to include multiple A\/H3N2 strains with or without the B\/Yamagata strain in US adults aged 50\u201375 years: a phase 1\/2, open-label, randomised trial. Lancet Infect Dis. 2025;25(1):25\u201335. https:\/\/doi.org\/10.1016\/s1473-3099(24)00493-6.","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"791_CR65","doi-asserted-by":"publisher","first-page":"973","DOI":"10.3390\/v13060973","volume":"13","author":"Q-T Nguyen","year":"2021","unstructured":"Nguyen Q-T, Choi Y-K. Targeting antigens for universal influenza vaccine development. Viruses. 2021;13(6):973. https:\/\/doi.org\/10.3390\/v13060973.","journal-title":"Viruses"},{"issue":"5","key":"791_CR66","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1016\/j.molimm.2009.10.023","volume":"47","author":"JW Yewdell","year":"2010","unstructured":"Yewdell JW. Monoclonal antibodies specific for discontinuous epitopes direct refolding of influenza A virus hemagglutinin. Mol Immunol. 2010;47(5):1132\u20136. https:\/\/doi.org\/10.1016\/j.molimm.2009.10.023.","journal-title":"Mol Immunol"},{"issue":"1","key":"791_CR67","doi-asserted-by":"publisher","first-page":"5","DOI":"10.4049\/jimmunol.2101171","volume":"209","author":"K Nagashima","year":"2022","unstructured":"Nagashima K, Dzimianski JV, Han J, Abbadi N, Gingerich AD, Royer F, et al. The pre-existing human antibody repertoire to computationally optimized influenza H1 hemagglutinin vaccines. J Immunol. 2022;209(1):5\u201315. https:\/\/doi.org\/10.4049\/jimmunol.2101171.","journal-title":"J Immunol"},{"issue":"11","key":"791_CR68","doi-asserted-by":"publisher","first-page":"1916-28.e6","DOI":"10.1016\/j.chom.2025.09.015","volume":"33","author":"H Lv","year":"2025","unstructured":"Lv H, Huan YW, Teo QW, Chen C, Pholcharee T, Gopal AB, et al. Evolution of antibody cross-reactivity to influenza H5N1 neuraminidase from an N2-specific germline. Cell Host Microbe. 2025;33(11):1916-28.e6. https:\/\/doi.org\/10.1016\/j.chom.2025.09.015.","journal-title":"Cell Host Microbe"},{"issue":"10","key":"791_CR69","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1089\/vim.2015.0060","volume":"28","author":"N Lohia","year":"2015","unstructured":"Lohia N, Baranwal M. Identification of conserved peptides comprising multiple T cell epitopes of matrix 1 protein in H1N1 influenza virus. Viral Immunol. 2015;28(10):570\u20139. https:\/\/doi.org\/10.1089\/vim.2015.0060.","journal-title":"Viral Immunol"},{"issue":"Supplement_1","key":"791_CR70","doi-asserted-by":"publisher","first-page":"S62","DOI":"10.1093\/infdis\/jiy711","volume":"219","author":"F Krammer","year":"2019","unstructured":"Krammer F, Palese P. Universal influenza virus vaccines that target the conserved hemagglutinin stalk and conserved sites in the head domain. J Infect Dis. 2019;219(Supplement_1):S62\u20137. https:\/\/doi.org\/10.1093\/infdis\/jiy711.","journal-title":"J Infect Dis"},{"key":"791_CR71","doi-asserted-by":"publisher","first-page":"786617","DOI":"10.3389\/fimmu.2021.786617","volume":"12","author":"S Creytens","year":"2021","unstructured":"Creytens S, Pascha MN, Ballegeer M, Saelens X, de Haan CAM. Influenza neuraminidase characteristics and potential as a vaccine target. Front Immunol. 2021;12:786617. https:\/\/doi.org\/10.3389\/fimmu.2021.786617.","journal-title":"Front Immunol"},{"issue":"11","key":"791_CR72","doi-asserted-by":"publisher","first-page":"2621-34.e6","DOI":"10.1016\/j.immuni.2023.10.005","volume":"56","author":"R Lei","year":"2023","unstructured":"Lei R, Kim W, Lv H, Mou Z, Scherm MJ, Schmitz AJ, et al. Leveraging vaccination-induced protective antibodies to define conserved epitopes on influenza N2 neuraminidase. Immunity. 2023;56(11):2621-34.e6. https:\/\/doi.org\/10.1016\/j.immuni.2023.10.005.","journal-title":"Immunity"},{"issue":"28","key":"791_CR73","doi-asserted-by":"publisher","first-page":"12658","DOI":"10.1073\/pnas.0911806107","volume":"107","author":"AG Grandea","year":"2010","unstructured":"Grandea AG, Olsen OA, Cox TC, Renshaw M, Hammond PW, Chan-Hui P-Y, et al. Human antibodies reveal a protective epitope that is highly conserved among human and nonhuman influenza A viruses. Proc Natl Acad Sci. 2010;107(28):12658\u201363. https:\/\/doi.org\/10.1073\/pnas.0911806107.","journal-title":"Proc Natl Acad Sci"},{"issue":"11","key":"791_CR74","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1080\/14760584.2018.1541408","volume":"17","author":"Y Wang","year":"2018","unstructured":"Wang Y, Deng L, Kang S-M, Wang B-Z. Universal influenza vaccines: from viruses to nanoparticles. Expert Rev Vaccines. 2018;17(11):967\u201376. https:\/\/doi.org\/10.1080\/14760584.2018.1541408.","journal-title":"Expert Rev Vaccines"},{"issue":"12","key":"791_CR75","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.3390\/vaccines11121747","volume":"11","author":"A Rak","year":"2023","unstructured":"Rak A, Isakova-Sivak I, Rudenko L. Nucleoprotein as a promising antigen for broadly protective influenza vaccines. Vaccines. 2023;11(12):1747. https:\/\/doi.org\/10.3390\/vaccines11121747.","journal-title":"Vaccines"},{"issue":"4","key":"791_CR76","doi-asserted-by":"publisher","first-page":"169","DOI":"10.3390\/vaccines7040169","volume":"7","author":"SD Jazayeri","year":"2019","unstructured":"Jazayeri SD, Poh CL. Development of universal influenza vaccines targeting conserved viral proteins. Vaccines. 2019;7(4):169. https:\/\/doi.org\/10.3390\/vaccines7040169.","journal-title":"Vaccines"},{"issue":"3","key":"791_CR77","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1002\/mlf2.12085","volume":"2","author":"Y Li","year":"2023","unstructured":"Li Y, Wang X, Zeng X, Ren W, Liao P, Zhu B. Protective efficacy of a universal influenza mRNA vaccine against the challenge of H1 and H5 influenza A viruses in mice. mLife. 2023;2(3):308\u201316. https:\/\/doi.org\/10.1002\/mlf2.12085.","journal-title":"mLife"},{"issue":"32","key":"791_CR78","doi-asserted-by":"publisher","first-page":"4412","DOI":"10.1016\/j.vaccine.2022.03.063","volume":"40","author":"JA Flynn","year":"2022","unstructured":"Flynn JA, Weber T, Cejas PJ, Cox KS, Touch S, Austin LA, et al. Characterization of humoral and cell-mediated immunity induced by mRNA vaccines expressing influenza hemagglutinin stem and nucleoprotein in mice and nonhuman primates. Vaccine. 2022;40(32):4412\u201323. https:\/\/doi.org\/10.1016\/j.vaccine.2022.03.063.","journal-title":"Vaccine"},{"key":"791_CR79","doi-asserted-by":"publisher","first-page":"110125","DOI":"10.1016\/j.virol.2024.110125","volume":"596","author":"Y Tian","year":"2024","unstructured":"Tian Y, Deng Z, Chuai Z, Li C, Chang L, Sun F, et al. A combination influenza mRNA vaccine candidate provided broad protection against diverse influenza virus challenge. Virology. 2024;596:110125. https:\/\/doi.org\/10.1016\/j.virol.2024.110125.","journal-title":"Virology"},{"issue":"1","key":"791_CR80","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1093\/jimmun\/vkae013","volume":"214","author":"P Grovenstein","year":"2025","unstructured":"Grovenstein P, Bhatnagar N, Kim K-H, Pal SS, Le CTT, Raha JR, et al. Influenza 5xM2e mRNA lipid nanoparticle vaccine confers broad immunity and significantly enhances the efficacy of inactivated split vaccination when coadministered. J Immunol. 2025;214(1):104\u201314. https:\/\/doi.org\/10.1093\/jimmun\/vkae013.","journal-title":"J Immunol"},{"key":"791_CR81","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2025.102690","author":"Z Cheng","year":"2025","unstructured":"Cheng Z, Sun Y, Bai Y, Wu X, Sun Z, Zhang Q, et al. mRNA vaccine based on high-frequency prevalent antigens provides broad protection against influenza B virus. Mol Ther Nucleic Acids. 2025. https:\/\/doi.org\/10.1016\/j.omtn.2025.102690.","journal-title":"Mol Ther Nucleic Acids."},{"issue":"7","key":"791_CR82","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1016\/j.ymthe.2020.04.018","volume":"28","author":"AW Freyn","year":"2020","unstructured":"Freyn AW, Ramos Da Silva J, Rosado VC, Bliss CM, Pine M, Mui BL, et al. A multi-targeting, nucleoside-modified mRNA influenza virus vaccine provides broad protection in mice. Mol Ther. 2020;28(7):1569\u201384. https:\/\/doi.org\/10.1016\/j.ymthe.2020.04.018.","journal-title":"Mol Ther"},{"issue":"45","key":"791_CR83","doi-asserted-by":"publisher","first-page":"e2206333119","DOI":"10.1073\/pnas.2206333119","volume":"119","author":"M McMahon","year":"2022","unstructured":"McMahon M, O\u2019Dell G, Tan J, S\u00e1rk\u00f6zy A, Vadovics M, Carre\u00f1o JM, et al. Assessment of a quadrivalent nucleoside-modified mRNA vaccine that protects against group 2 influenza viruses. Proc Natl Acad Sci. 2022;119(45):e2206333119. https:\/\/doi.org\/10.1073\/pnas.2206333119.","journal-title":"Proc Natl Acad Sci"},{"issue":"3","key":"791_CR84","doi-asserted-by":"publisher","first-page":"257","DOI":"10.3390\/vaccines9030257","volume":"9","author":"BL Bullard","year":"2021","unstructured":"Bullard BL, Weaver EA. Strategies targeting hemagglutinin as a universal influenza vaccine. Vaccines. 2021;9(3):257. https:\/\/doi.org\/10.3390\/vaccines9030257.","journal-title":"Vaccines"},{"key":"791_CR85","doi-asserted-by":"publisher","first-page":"344","DOI":"10.3389\/fcimb.2019.00344","volume":"9","author":"YH Jang","year":"2019","unstructured":"Jang YH, Seong BL. The quest for a truly universal influenza vaccine. Front Cell Infect Microbiol. 2019;9:344. https:\/\/doi.org\/10.3389\/fcimb.2019.00344.","journal-title":"Front Cell Infect Microbiol"},{"issue":"27","key":"791_CR86","doi-asserted-by":"publisher","first-page":"25526","DOI":"10.1021\/acsnano.5c08831","volume":"19","author":"C Dong","year":"2025","unstructured":"Dong C, Wei L, Zhu W, Kim JK, Wang Y, Omotara P, et al. Mature dendritic cell-derived extracellular vesicles are potent mucosal adjuvants for influenza hemagglutinin vaccines. ACS Nano. 2025;19(27):25526\u201342. https:\/\/doi.org\/10.1021\/acsnano.5c08831.","journal-title":"ACS Nano"},{"issue":"1","key":"791_CR87","doi-asserted-by":"publisher","first-page":"120","DOI":"10.3390\/v16010120","volume":"16","author":"L Wei","year":"2024","unstructured":"Wei L, Dong C, Zhu W, Wang B-Z. mRNA vaccine nanoplatforms and innate immunity. Viruses. 2024;16(1):120. https:\/\/doi.org\/10.3390\/v16010120.","journal-title":"Viruses"},{"issue":"9","key":"791_CR88","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.3390\/v14091905","volume":"14","author":"J He","year":"2022","unstructured":"He J, Yu L, Lin X, Liu X, Zhang Y, Yang F, et al. Virus-like particles as nanocarriers for intracellular delivery of biomolecules and compounds. Viruses. 2022;14(9):1905. https:\/\/doi.org\/10.3390\/v14091905.","journal-title":"Viruses"},{"issue":"1","key":"791_CR89","doi-asserted-by":"publisher","first-page":"2453304","DOI":"10.1080\/21645515.2025.2453304","volume":"21","author":"L Xu","year":"2025","unstructured":"Xu L, Yu Z, Xu Y, Wang Q, Wang G, Li B, et al. An mRNA vaccine candidate encoding cholera toxin subunit B and conserved antigens of influenza viruses confers cross-protection against influenza a viruses in adult and aged mice. Hum Vaccin Immunother. 2025;21(1):2453304. https:\/\/doi.org\/10.1080\/21645515.2025.2453304.","journal-title":"Hum Vaccin Immunother"},{"issue":"2","key":"791_CR90","doi-asserted-by":"publisher","first-page":"e03589-24","DOI":"10.1128\/mbio.03589-24","volume":"16","author":"V Gnazzo","year":"2025","unstructured":"Gnazzo V, Saleh H, Castro \u00cdA, Boon ACM, Pinto AK, Brien JD, et al. DDO-adjuvanted influenza A virus nucleoprotein mRNA vaccine induces robust humoral and cellular type 1 immune responses and protects mice from challenge. MBio. 2025;16(2):e03589-24. https:\/\/doi.org\/10.1128\/mbio.03589-24.","journal-title":"MBio"},{"key":"791_CR91","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.omtn.2022.10.024","volume":"30","author":"W Zhu","year":"2022","unstructured":"Zhu W, Wei L, Dong C, Wang Y, Kim J, Ma Y, et al. cGAMP-adjuvanted multivalent influenza mRNA vaccines induce broadly protective immunity through cutaneous vaccination in mice. Mol Ther Nucleic Acids. 2022;30:421\u201337. https:\/\/doi.org\/10.1016\/j.omtn.2022.10.024.","journal-title":"Mol Ther Nucleic Acids"},{"key":"791_CR92","doi-asserted-by":"publisher","first-page":"123039","DOI":"10.1016\/j.biomaterials.2024.123039","volume":"317","author":"L Wei","year":"2025","unstructured":"Wei L, Zhu W, Dong C, Kim JK, Ma Y, Denning TL, et al. Lipid nanoparticles encapsulating both adjuvant and antigen mRNA improve influenza immune cross-protection in mice. Biomaterials. 2025;317:123039. https:\/\/doi.org\/10.1016\/j.biomaterials.2024.123039.","journal-title":"Biomaterials"},{"issue":"4","key":"791_CR93","doi-asserted-by":"publisher","first-page":"566","DOI":"10.3390\/v17040566","volume":"17","author":"T Vallet","year":"2025","unstructured":"Vallet T, Vignuzzi M. Self-amplifying RNA: advantages and challenges of a versatile platform for vaccine development. Viruses. 2025;17(4):566. https:\/\/doi.org\/10.3390\/v17040566.","journal-title":"Viruses"},{"issue":"1","key":"791_CR94","doi-asserted-by":"publisher","first-page":"138","DOI":"10.3390\/pathogens12010138","volume":"12","author":"C Schmidt","year":"2023","unstructured":"Schmidt C, Schnierle BS. Self-amplifying RNA vaccine candidates: alternative platforms for mRNA vaccine development. Pathogens. 2023;12(1):138. https:\/\/doi.org\/10.3390\/pathogens12010138.","journal-title":"Pathogens"},{"key":"791_CR95","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.actbio.2021.06.023","volume":"131","author":"EH Pilkington","year":"2021","unstructured":"Pilkington EH, Suys EJA, Trevaskis NL, Wheatley AK, Zukancic D, Algarni A, et al. From influenza to COVID-19: lipid nanoparticle mRNA vaccines at the frontiers of infectious diseases. Acta Biomater. 2021;131:16\u201340. https:\/\/doi.org\/10.1016\/j.actbio.2021.06.023.","journal-title":"Acta Biomater"},{"issue":"2","key":"791_CR96","doi-asserted-by":"publisher","first-page":"97","DOI":"10.3390\/vaccines9020097","volume":"9","author":"AK Blakney","year":"2021","unstructured":"Blakney AK, Ip S, Geall AJ. An update on self-amplifying mRNA vaccine development. Vaccines. 2021;9(2):97. https:\/\/doi.org\/10.3390\/vaccines9020097.","journal-title":"Vaccines"},{"key":"791_CR97","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.coviro.2020.08.003","volume":"44","author":"MC Ballesteros-Briones","year":"2020","unstructured":"Ballesteros-Briones MC, Silva-Pilipich N, Herrador-Ca\u00f1ete G, Vanrell L, Smerdou C. A new generation of vaccines based on alphavirus self-amplifying RNA. Curr Opin Virol. 2020;44:145\u201353. https:\/\/doi.org\/10.1016\/j.coviro.2020.08.003.","journal-title":"Curr Opin Virol"},{"issue":"6","key":"791_CR98","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1016\/j.ymthe.2025.03.060","volume":"33","author":"IC Casmil","year":"2025","unstructured":"Casmil IC, Jin J, Won E-J, Huang C, Liao S, Cha-Molstad H, et al. The advent of clinical self-amplifying RNA vaccines. Mol Ther. 2025;33(6):2565\u201382. https:\/\/doi.org\/10.1016\/j.ymthe.2025.03.060.","journal-title":"Mol Ther"},{"key":"791_CR99","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/s41434-020-00204-y","volume":"28","author":"K Bloom","year":"2021","unstructured":"Bloom K, Van Den Berg F, Arbuthnot P. Self-amplifying RNA vaccines for infectious diseases. Gene Ther. 2021;28:117\u201329. https:\/\/doi.org\/10.1038\/s41434-020-00204-y.","journal-title":"Gene Ther"},{"issue":"3","key":"791_CR100","doi-asserted-by":"publisher","first-page":"318","DOI":"10.3390\/vaccines12030318","volume":"12","author":"N Silva-Pilipich","year":"2024","unstructured":"Silva-Pilipich N, Beloki U, Salaberry L, Smerdou C. Self-amplifying RNA: a second revolution of mRNA vaccines against COVID-19. Vaccines. 2024;12(3):318. https:\/\/doi.org\/10.3390\/vaccines12030318.","journal-title":"Vaccines"},{"issue":"4","key":"791_CR101","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1042\/bio_2021_142","volume":"43","author":"A Blakney","year":"2021","unstructured":"Blakney A. The next generation of RNA vaccines: self-amplifying RNA. Biochemist. 2021;43(4):14\u20137. https:\/\/doi.org\/10.1042\/bio_2021_142.","journal-title":"Biochemist"},{"issue":"1","key":"791_CR102","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1038\/s41541-023-00747-2","volume":"8","author":"M Cheung","year":"2023","unstructured":"Cheung M, Chang C, Rathnasinghe R, Rossignol E, Zhang Y, Ferrari A, et al. Self-amplifying mRNA seasonal influenza vaccines elicit mouse neutralizing antibody and cell-mediated immunity and protect ferrets. npj Vaccines. 2023;8(1):150. https:\/\/doi.org\/10.1038\/s41541-023-00747-2.","journal-title":"npj Vaccines"},{"issue":"1","key":"791_CR103","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1038\/s41541-024-00932-x","volume":"9","author":"X Cui","year":"2024","unstructured":"Cui X, Vervaeke P, Gao Y, Opsomer L, Sun Q, Snoeck J, et al. Immunogenicity and biodistribution of lipid nanoparticle formulated self-amplifying mRNA vaccines against H5 avian influenza. npj Vaccines. 2024;9(1):138. https:\/\/doi.org\/10.1038\/s41541-024-00932-x.","journal-title":"npj Vaccines."},{"key":"791_CR104","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-64829-6","author":"MR Ykema","year":"2026","unstructured":"Ykema MR, Davis MA, Kasal DN, Jennewein MF, Lo E, Singh J, et al. Intranasal replicon vaccine establishes mucosal immunity and protects against H5N1 and H7N9 influenza. Nat Commun. 2026. https:\/\/doi.org\/10.1038\/s41467-025-64829-6.","journal-title":"Nat Commun"},{"issue":"1","key":"791_CR105","doi-asserted-by":"publisher","first-page":"iqac004","DOI":"10.1093\/oxfimm\/iqac004","volume":"3","author":"PF McKay","year":"2022","unstructured":"McKay PF, Zhou J, Frise R, Blakney AK, Bouton CR, Wang Z, et al. Polymer formulated self-amplifying RNA vaccine is partially protective against influenza virus infection in ferrets. Oxf Open Immunol. 2022;3(1):iqac004. https:\/\/doi.org\/10.1093\/oxfimm\/iqac004.","journal-title":"Oxf Open Immunol."},{"issue":"8","key":"791_CR106","doi-asserted-by":"publisher","first-page":"1822.e1","DOI":"10.1016\/j.cell.2024.03.018","volume":"187","author":"CJ Wayne","year":"2024","unstructured":"Wayne CJ, Blakney AK. Self-amplifying RNA COVID-19 vaccine. Cell. 2024;187(8):1822.e1. https:\/\/doi.org\/10.1016\/j.cell.2024.03.018.","journal-title":"Cell"},{"issue":"1","key":"791_CR107","doi-asserted-by":"publisher","first-page":"4081","DOI":"10.1038\/s41467-024-47905-1","volume":"15","author":"NT H\u1ed3","year":"2024","unstructured":"H\u1ed3 NT, Hughes SG, Ta VT, Phan LT, \u0110\u1ed7 Q, Nguy\u1ec5n TV, et al. Safety, immunogenicity and efficacy of the self-amplifying mRNA ARCT-154 COVID-19 vaccine: pooled phase 1, 2, 3a and 3b randomized, controlled trials. Nat Commun. 2024;15(1):4081. https:\/\/doi.org\/10.1038\/s41467-024-47905-1.","journal-title":"Nat Commun"},{"issue":"4","key":"791_CR108","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/s1473-3099(23)00650-3","volume":"24","author":"Y Oda","year":"2024","unstructured":"Oda Y, Kumagai Y, Kanai M, Iwama Y, Okura I, Minamida T, et al. Immunogenicity and safety of a booster dose of a self-amplifying RNA COVID-19 vaccine (ARCT-154) versus BNT162b2 mRNA COVID-19 vaccine: a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial. Lancet Infect Dis. 2024;24(4):351\u201360. https:\/\/doi.org\/10.1016\/s1473-3099(23)00650-3.","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"791_CR109","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/s1473-3099(24)00060-4","volume":"24","author":"Y Oda","year":"2024","unstructured":"Oda Y, Kumagai Y, Kanai M, Iwama Y, Okura I, Minamida T, et al. Persistence of immune responses of a self-amplifying RNA COVID-19 vaccine (ARCT-154) versus BNT162b2. Lancet Infect Dis. 2024;24(4):341\u20133. https:\/\/doi.org\/10.1016\/s1473-3099(24)00060-4.","journal-title":"Lancet Infect Dis"},{"key":"791_CR110","doi-asserted-by":"publisher","first-page":"103428","DOI":"10.1016\/j.eclinm.2025.103428","volume":"87","author":"ML Giles","year":"2025","unstructured":"Giles ML, Tabora C, Baccarini C, Barrientos L, Vargas JC, Montellano ME, et al. Immunogenicity and safety of self-amplifying mRNA COVID-19 vaccine (ARCT-2303), with or without co-administration of seasonal inactivated influenza vaccine in adults: a phase 3, randomised, controlled, observer-blind, multicentre study. eClinicalMedicine. 2025;87:103428. https:\/\/doi.org\/10.1016\/j.eclinm.2025.103428.","journal-title":"eClinicalMedicine."},{"issue":"1","key":"791_CR111","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/s41541-022-00590-x","volume":"7","author":"JG Low","year":"2022","unstructured":"Low JG, De Alwis R, Chen S, Kalimuddin S, Leong YS, Mah TKL, et al. A phase I\/II randomized, double-blinded, placebo-controlled trial of a self-amplifying Covid-19 mRNA vaccine. npj Vaccines. 2022;7(1):161. https:\/\/doi.org\/10.1038\/s41541-022-00590-x.","journal-title":"npj Vaccines."},{"key":"791_CR112","doi-asserted-by":"publisher","first-page":"101823","DOI":"10.1016\/j.eclinm.2022.101823","volume":"56","author":"AJ Szubert","year":"2023","unstructured":"Szubert AJ, Pollock KM, Cheeseman HM, Alagaratnam J, Bern H, Bird O, et al. COVAC1 phase 2a expanded safety and immunogenicity study of a self-amplifying RNA vaccine against SARS-CoV-2. eClinicalMedicine. 2023;56:101823. https:\/\/doi.org\/10.1016\/j.eclinm.2022.101823.","journal-title":"eClinicalMedicine."},{"issue":"1","key":"791_CR113","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/s41392-023-01561-x","volume":"8","author":"D Niu","year":"2023","unstructured":"Niu D, Wu Y, Lian J. Circular RNA vaccine in disease prevention and treatment. Signal Transduct Target Ther. 2023;8(1):341. https:\/\/doi.org\/10.1038\/s41392-023-01561-x.","journal-title":"Signal Transduct Target Ther"},{"issue":"6","key":"791_CR114","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1038\/s12276-024-01220-3","volume":"56","author":"HJ Hwang","year":"2024","unstructured":"Hwang HJ, Kim YK. Molecular mechanisms of circular RNA translation. Exp Mol Med. 2024;56(6):1272\u201380. https:\/\/doi.org\/10.1038\/s12276-024-01220-3.","journal-title":"Exp Mol Med"},{"key":"791_CR115","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.jconrel.2022.05.043","volume":"348","author":"X Liu","year":"2022","unstructured":"Liu X, Zhang Y, Zhou S, Dain L, Mei L, Zhu G. Circular RNA: an emerging frontier in RNA therapeutic targets, RNA therapeutics, and mRNA vaccines. J Control Release. 2022;348:84\u201394. https:\/\/doi.org\/10.1016\/j.jconrel.2022.05.043.","journal-title":"J Control Release"},{"issue":"46","key":"791_CR116","doi-asserted-by":"publisher","first-page":"2303713","DOI":"10.1002\/smll.202303713","volume":"19","author":"C Bai","year":"2023","unstructured":"Bai C, Wang C, Lu Y. Novel vectors and administrations for mRNA delivery. Small. 2023;19(46):2303713. https:\/\/doi.org\/10.1002\/smll.202303713.","journal-title":"Small"},{"key":"791_CR117","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2025.114198","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Xu Y, Tang W, Zhou S, Liu X, Wang Z, et al. Pulmonary delivery of small circular RNA vaccines for influenza prevention. J Controlled Release. 2025. https:\/\/doi.org\/10.1016\/j.jconrel.2025.114198.","journal-title":"J Controlled Release."},{"issue":"1","key":"791_CR118","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/s41541-024-00963-4","volume":"9","author":"X Yue","year":"2024","unstructured":"Yue X, Zhong C, Cao R, Liu S, Qin Z, Liu L, et al. CircRNA based multivalent neuraminidase vaccine induces broad protection against influenza viruses in mice. npj Vaccines. 2024;9(1):170. https:\/\/doi.org\/10.1038\/s41541-024-00963-4.","journal-title":"npj Vaccines."},{"issue":"20","key":"791_CR119","doi-asserted-by":"publisher","first-page":"e2302191120","DOI":"10.1073\/pnas.2302191120","volume":"120","author":"L Amaya","year":"2023","unstructured":"Amaya L, Grigoryan L, Li Z, Lee A, Wender PA, Pulendran B, et al. Circular RNA vaccine induces potent T cell responses. Proc Natl Acad Sci USA. 2023;120(20):e2302191120. https:\/\/doi.org\/10.1073\/pnas.2302191120.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"8","key":"791_CR120","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1016\/j.ymthe.2024.06.019","volume":"32","author":"TAH Hick","year":"2024","unstructured":"Hick TAH, Geertsema C, Nguyen W, Bishop CR, Van Oosten L, Abbo SR, et al. Safety concern of recombination between self-amplifying mRNA vaccines and viruses is mitigated in vivo. Mol Ther. 2024;32(8):2519\u201334. https:\/\/doi.org\/10.1016\/j.ymthe.2024.06.019.","journal-title":"Mol Ther"},{"issue":"9","key":"791_CR121","doi-asserted-by":"publisher","first-page":"2968","DOI":"10.1016\/j.ymthe.2022.04.014","volume":"30","author":"S McCafferty","year":"2022","unstructured":"McCafferty S, Haque AKMA, Vandierendonck A, Weidensee B, Plovyt M, Stuchl\u00edkov\u00e1 M, et al. A dual-antigen self-amplifying RNA SARS-CoV-2 vaccine induces potent humoral and cellular immune responses and protects against SARS-CoV-2 variants through T cell-mediated immunity. Mol Ther. 2022;30(9):2968\u201383. https:\/\/doi.org\/10.1016\/j.ymthe.2022.04.014.","journal-title":"Mol Ther"},{"issue":"3","key":"791_CR122","doi-asserted-by":"publisher","first-page":"102687","DOI":"10.1016\/j.omtn.2025.102687","volume":"36","author":"K Chen","year":"2025","unstructured":"Chen K, Xu Y, Li J, Gu S, Wang Z, Li J, et al. The potential and challenges of circular RNA in the development of vaccines and drugs for emerging infectious diseases. Mol Ther Nucleic Acids. 2025;36(3):102687. https:\/\/doi.org\/10.1016\/j.omtn.2025.102687.","journal-title":"Mol Ther Nucleic Acids"},{"key":"791_CR123","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.ymeth.2021.02.020","volume":"196","author":"P Obi","year":"2021","unstructured":"Obi P, Chen YG. The design and synthesis of circular RNAs. Methods. 2021;196:85\u2013103. https:\/\/doi.org\/10.1016\/j.ymeth.2021.02.020.","journal-title":"Methods"},{"issue":"5","key":"791_CR124","doi-asserted-by":"publisher","first-page":"e01295-23","DOI":"10.1128\/mbio.01295-23","volume":"14","author":"R Heida","year":"2023","unstructured":"Heida R, Frijlink HW, Hinrichs WLJ. Inhalation of vaccines and antiviral drugs to fight respiratory virus infections: reasons to prioritize the pulmonary route of administration. MBio. 2023;14(5):e01295-23. https:\/\/doi.org\/10.1128\/mbio.01295-23.","journal-title":"MBio"},{"issue":"23","key":"791_CR125","doi-asserted-by":"publisher","first-page":"4262","DOI":"10.1021\/acs.accounts.1c00493","volume":"54","author":"M Qin","year":"2021","unstructured":"Qin M, Du G, Sun X. Recent advances in the noninvasive delivery of mRNA. Acc Chem Res. 2021;54(23):4262\u201371. https:\/\/doi.org\/10.1021\/acs.accounts.1c00493.","journal-title":"Acc Chem Res"},{"issue":"4","key":"791_CR126","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1007\/s13346-020-00891-5","volume":"12","author":"L-A Keller","year":"2022","unstructured":"Keller L-A, Merkel O, Popp A. Intranasal drug delivery: opportunities and toxicologic challenges during drug development. Drug Deliv Transl Res. 2022;12(4):735\u201357. https:\/\/doi.org\/10.1007\/s13346-020-00891-5.","journal-title":"Drug Deliv Transl Res"},{"issue":"3","key":"791_CR127","doi-asserted-by":"publisher","first-page":"306","DOI":"10.4168\/aair.2019.11.3.306","volume":"11","author":"J Jiao","year":"2019","unstructured":"Jiao J, Zhang L. Influence of intranasal drugs on human nasal mucociliary clearance and ciliary beat frequency. Allergy Asthma Immunol Res. 2019;11(3):306. https:\/\/doi.org\/10.4168\/aair.2019.11.3.306.","journal-title":"Allergy Asthma Immunol Res"},{"issue":"11","key":"791_CR128","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1080\/17425247.2022.2131767","volume":"19","author":"EM Jansen","year":"2022","unstructured":"Jansen EM, Frijlink HW, Hinrichs WL, Ruigrok M Jr. Are inhaled mRNA vaccines safe and effective? A review of preclinical studies. Expert Opin Drug Deliv. 2022;19(11):1471\u201385. https:\/\/doi.org\/10.1080\/17425247.2022.2131767.","journal-title":"Expert Opin Drug Deliv"},{"key":"791_CR129","doi-asserted-by":"publisher","first-page":"8085","DOI":"10.2147\/ijn.s517385","volume":"20","author":"Y Tayyar","year":"2025","unstructured":"Tayyar Y, Idris A, Yassine H. Intranasal and pulmonary lipid nanoparticles for gene delivery: turning challenges into opportunities. Int J Nanomed. 2025;20:8085\u201399. https:\/\/doi.org\/10.2147\/ijn.s517385.","journal-title":"Int J Nanomed"},{"issue":"5","key":"791_CR130","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.3390\/pharmaceutics14051073","volume":"14","author":"J Tai","year":"2022","unstructured":"Tai J, Han M, Lee D, Park I-H, Lee SH, Kim TH. Different methods and formulations of drugs and vaccines for nasal administration. Pharmaceutics. 2022;14(5):1073. https:\/\/doi.org\/10.3390\/pharmaceutics14051073.","journal-title":"Pharmaceutics"},{"key":"791_CR131","doi-asserted-by":"publisher","DOI":"10.1002\/iid3.604","author":"S Kar","year":"2022","unstructured":"Kar S, Devnath P, Emran TB, Tallei TE, Mitra S, Dhama K. Oral and intranasal vaccines against SARS-CoV-2: current progress, prospects, advantages, and challenges. Immun Inflamm Dis. 2022. https:\/\/doi.org\/10.1002\/iid3.604.","journal-title":"Immun Inflamm Dis."},{"issue":"10","key":"791_CR132","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1093\/intimm\/dxx064","volume":"29","author":"Y Date","year":"2017","unstructured":"Date Y, Ebisawa M, Fukuda S, Shima H, Obata Y, Takahashi D, et al. NALT M cells are important for immune induction for the common mucosal immune system. Int Immunol. 2017;29(10):471\u20138. https:\/\/doi.org\/10.1093\/intimm\/dxx064.","journal-title":"Int Immunol"},{"key":"791_CR133","doi-asserted-by":"publisher","DOI":"10.1186\/s43556-025-00301-7","author":"Z Zhang","year":"2025","unstructured":"Zhang Z, Hong W, Zhang Y, Li X, Que H, Wei X. Mucosal immunity and vaccination strategies: current insights and future perspectives. Mol Biomed. 2025. https:\/\/doi.org\/10.1186\/s43556-025-00301-7.","journal-title":"Mol Biomed."},{"key":"791_CR134","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20251901","author":"J Liu","year":"2026","unstructured":"Liu J, Stoler-Barak L, Shulman Z. Nasal germinal centers and IgA class-switch recombination depend on CCR6 and B cell receptor affinity. J Exp Med. 2026. https:\/\/doi.org\/10.1084\/jem.20251901.","journal-title":"J Exp Med"},{"issue":"8","key":"791_CR135","doi-asserted-by":"publisher","first-page":"4507","DOI":"10.4049\/jimmunol.0900237","volume":"182","author":"Z Jaffar","year":"2009","unstructured":"Jaffar Z, Ferrini ME, Herritt LA, Roberts K. Cutting edge: lung mucosal Th17-mediated responses induce polymeric ig receptor expression by the airway epithelium and elevate secretory IgA levels. J Immunol. 2009;182(8):4507\u201311. https:\/\/doi.org\/10.4049\/jimmunol.0900237.","journal-title":"J Immunol"},{"issue":"5","key":"791_CR136","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.3390\/ijms22052284","volume":"22","author":"H Wei","year":"2021","unstructured":"Wei H, Wang J-Y. Role of polymeric immunoglobulin receptor in IgA and IgM transcytosis. Int J Mol Sci. 2021;22(5):2284. https:\/\/doi.org\/10.3390\/ijms22052284.","journal-title":"Int J Mol Sci"},{"issue":"38","key":"791_CR137","doi-asserted-by":"publisher","first-page":"eadh1655","DOI":"10.1126\/sciadv.adh1655","volume":"9","author":"G Baldeon Vaca","year":"2023","unstructured":"Baldeon Vaca G, Meyer M, Cadete A, Hsiao CJ, Golding A, Jeon A, et al. Intranasal mRNA-LNP vaccination protects hamsters from SARS-CoV-2 infection. Sci Adv. 2023;9(38):eadh1655. https:\/\/doi.org\/10.1126\/sciadv.adh1655.","journal-title":"Sci Adv"},{"issue":"3","key":"791_CR138","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1038\/s41565-023-01548-3","volume":"19","author":"AY Jiang","year":"2024","unstructured":"Jiang AY, Witten J, Raji IO, Eweje F, Macisaac C, Meng S, et al. Combinatorial development of nebulized mRNA delivery formulations for the lungs. Nat Nanotechnol. 2024;19(3):364\u201375. https:\/\/doi.org\/10.1038\/s41565-023-01548-3.","journal-title":"Nat Nanotechnol"},{"key":"791_CR139","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.jconrel.2021.12.027","volume":"344","author":"H Parhiz","year":"2022","unstructured":"Parhiz H, Brenner JS, Patel PN, Papp TE, Shahnawaz H, Li Q, et al. Added to pre-existing inflammation, mRNA-lipid nanoparticles induce inflammation exacerbation (IE). J Control Release. 2022;344:50\u201361. https:\/\/doi.org\/10.1016\/j.jconrel.2021.12.027.","journal-title":"J Control Release"},{"issue":"4","key":"791_CR140","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1038\/s41590-022-01160-y","volume":"23","author":"S Tahtinen","year":"2022","unstructured":"Tahtinen S, Tong A-J, Himmels P, Oh J, Paler-Martinez A, Kim L, et al. IL-1 and IL-1ra are key regulators of the inflammatory response to RNA vaccines. Nat Immunol. 2022;23(4):532\u201342. https:\/\/doi.org\/10.1038\/s41590-022-01160-y.","journal-title":"Nat Immunol"},{"issue":"6","key":"791_CR141","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1016\/j.ymthe.2022.04.011","volume":"30","author":"SM Moghimi","year":"2022","unstructured":"Moghimi SM, Simberg D. Pro-inflammatory concerns with lipid nanoparticles. Mol Ther. 2022;30(6):2109\u201310. https:\/\/doi.org\/10.1016\/j.ymthe.2022.04.011.","journal-title":"Mol Ther"},{"issue":"12","key":"791_CR142","doi-asserted-by":"publisher","first-page":"103479","DOI":"10.1016\/j.isci.2021.103479","volume":"24","author":"S Ndeupen","year":"2021","unstructured":"Ndeupen S, Qin Z, Jacobsen S, Bouteau A, Estanbouli H, Igy\u00e1rt\u00f3 BZ. The mRNA-LNP platform\u2019s lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory. iScience. 2021;24(12):103479. https:\/\/doi.org\/10.1016\/j.isci.2021.103479.","journal-title":"iScience."},{"issue":"6","key":"791_CR143","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1016\/j.ymthe.2024.12.019","volume":"33","author":"H-M Nguyen","year":"2025","unstructured":"Nguyen H-M, Alexander KE, Collinge M, Hickey JC, Lanz TA, Li J, et al. mRNA-LNPs induce immune activation and cytokine release in human whole blood assays across diverse health conditions. Mol Ther. 2025;33(6):2872\u201385. https:\/\/doi.org\/10.1016\/j.ymthe.2024.12.019.","journal-title":"Mol Ther"},{"issue":"5","key":"791_CR144","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1002\/jbm.a.37356","volume":"110","author":"H Zhang","year":"2022","unstructured":"Zhang H, Han X, Alameh MG, Shepherd SJ, Padilla MS, Xue L, et al. Rational design of anti\u2010inflammatory lipid nanoparticles for mRNA delivery. J Biomed Mater Res A. 2022;110(5):1101\u20138. https:\/\/doi.org\/10.1002\/jbm.a.37356.","journal-title":"J Biomed Mater Res A"},{"issue":"2","key":"791_CR145","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.ymthe.2024.12.032","volume":"33","author":"A Kawai","year":"2025","unstructured":"Kawai A, Shimizu T, Tanaka H, Shichinohe S, Anindita J, Hirose M, et al. Low-inflammatory lipid nanoparticle-based mRNA vaccine elicits protective immunity against H5N1 influenza virus with reduced adverse reactions. Mol Ther. 2025;33(2):529\u201347. https:\/\/doi.org\/10.1016\/j.ymthe.2024.12.032.","journal-title":"Mol Ther"},{"issue":"11","key":"791_CR146","doi-asserted-by":"publisher","first-page":"2407383","DOI":"10.1002\/advs.202407383","volume":"12","author":"N Maniyamgama","year":"2025","unstructured":"Maniyamgama N, Bae KH, Chang ZW, Lee J, Ang MJY, Tan YJ, et al. Muco-penetrating lipid nanoparticles having a liquid core for enhanced intranasal mRNA delivery. Adv Sci. 2025;12(11):2407383. https:\/\/doi.org\/10.1002\/advs.202407383.","journal-title":"Adv Sci"},{"key":"791_CR147","doi-asserted-by":"publisher","first-page":"102871","DOI":"10.1016\/j.cis.2023.102871","volume":"314","author":"P Grav\u00e1n","year":"2023","unstructured":"Grav\u00e1n P, Aguilera-Garrido A, Marchal JA, Navarro-Marchal SA, Galisteo-Gonz\u00e1lez F. Lipid-core nanoparticles: classification, preparation methods, routes of administration and recent advances in cancer treatment. Adv Colloid Interface Sci. 2023;314:102871. https:\/\/doi.org\/10.1016\/j.cis.2023.102871.","journal-title":"Adv Colloid Interface Sci"},{"issue":"1","key":"791_CR148","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s40824-023-00425-3","volume":"27","author":"M Yuan","year":"2023","unstructured":"Yuan M, Han Z, Liang Y, Sun Y, He B, Chen W, et al. mRNA nanodelivery systems: targeting strategies and administration routes. Biomater Res. 2023;27(1):90. https:\/\/doi.org\/10.1186\/s40824-023-00425-3.","journal-title":"Biomater Res."},{"issue":"709","key":"791_CR149","doi-asserted-by":"publisher","first-page":"eabq0603","DOI":"10.1126\/scitranslmed.abq0603","volume":"15","author":"A Suberi","year":"2023","unstructured":"Suberi A, Grun MK, Mao T, Israelow B, Reschke M, Grundler J, et al. Polymer nanoparticles deliver mRNA to the lung for mucosal vaccination. Sci Transl Med. 2023;15(709):eabq0603. https:\/\/doi.org\/10.1126\/scitranslmed.abq0603.","journal-title":"Sci Transl Med."},{"issue":"3","key":"791_CR150","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/s41563-022-01404-0","volume":"22","author":"L Rotolo","year":"2023","unstructured":"Rotolo L, Vanover D, Bruno NC, Peck HE, Zurla C, Murray J, et al. Species-agnostic polymeric formulations for inhalable messenger RNA delivery to the lung. Nat Mater. 2023;22(3):369\u201379. https:\/\/doi.org\/10.1038\/s41563-022-01404-0.","journal-title":"Nat Mater"},{"key":"791_CR151","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejpb.2022.05.002","volume":"176","author":"P Henriques","year":"2022","unstructured":"Henriques P, Fortuna A, Doktorovov\u00e1 S. Spray dried powders for nasal delivery: process and formulation considerations. Eur J Pharm Biopharm. 2022;176:1\u201320. https:\/\/doi.org\/10.1016\/j.ejpb.2022.05.002.","journal-title":"Eur J Pharm Biopharm"},{"issue":"9","key":"791_CR152","doi-asserted-by":"publisher","first-page":"2960","DOI":"10.1016\/j.matt.2022.06.012","volume":"5","author":"KD Popowski","year":"2022","unstructured":"Popowski KD, Moatti A, Scull G, Silkstone D, Lutz H, L\u00f3pez De Juan Abad B, et al. Inhalable dry powder mRNA vaccines based on extracellular vesicles. Matter. 2022;5(9):2960\u201374. https:\/\/doi.org\/10.1016\/j.matt.2022.06.012.","journal-title":"Matter"},{"issue":"1","key":"791_CR153","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2022\/3692065","volume":"2022","author":"S Assadpour","year":"2022","unstructured":"Assadpour S, Shiran MR, Asadi P, Akhtari J, Sahebkar A. Harnessing intranasal delivery systems of sumatriptan for the treatment of migraine. Biomed Res Int. 2022;2022(1):1\u20139. https:\/\/doi.org\/10.1155\/2022\/3692065.","journal-title":"Biomed Res Int"},{"issue":"9","key":"791_CR154","doi-asserted-by":"publisher","first-page":"6228","DOI":"10.1097\/ms9.0000000000003652","volume":"87","author":"AAA Basaria","year":"2025","unstructured":"Basaria AAA, Sah S, Ratnani H, Fatima I, Yokolo H. Atzumi for migraine a new era of needle-free dihydroergotamine delivery. Ann Med Surg. 2025;87(9):6228\u201330. https:\/\/doi.org\/10.1097\/ms9.0000000000003652.","journal-title":"Ann Med Surg."},{"key":"791_CR155","unstructured":"FDA. Pediatric postmarketing pharmacovigilance review. 2023. https:\/\/www.fda.gov\/media\/174996\/download. Accessed 14 Nov 2025."},{"issue":"4","key":"791_CR156","doi-asserted-by":"publisher","first-page":"390","DOI":"10.3390\/vaccines9040390","volume":"9","author":"F Kowalzik","year":"2021","unstructured":"Kowalzik F, Schreiner D, Jensen C, Teschner D, Gehring S, Zepp F. mRNA-based vaccines. Vaccines. 2021;9(4):390. https:\/\/doi.org\/10.3390\/vaccines9040390.","journal-title":"Vaccines"},{"issue":"3","key":"791_CR157","doi-asserted-by":"publisher","first-page":"668","DOI":"10.3390\/v15030668","volume":"15","author":"F Cheng","year":"2023","unstructured":"Cheng F, Wang Y, Bai Y, Liang Z, Mao Q, Liu D, et al. Research advances on the stability of mRNA vaccines. Viruses. 2023;15(3):668. https:\/\/doi.org\/10.3390\/v15030668.","journal-title":"Viruses"},{"issue":"2","key":"791_CR158","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.xphs.2023.11.023","volume":"113","author":"U Chheda","year":"2024","unstructured":"Chheda U, Pradeepan S, Esposito E, Strezsak S, Fernandez-Delgado O, Kranz J. Factors affecting stability of RNA\u2014temperature, length, concentration, pH, and buffering species. J Pharm Sci. 2024;113(2):377\u201385. https:\/\/doi.org\/10.1016\/j.xphs.2023.11.023.","journal-title":"J Pharm Sci"},{"issue":"15","key":"791_CR159","doi-asserted-by":"publisher","first-page":"2202688","DOI":"10.1002\/adhm.202202688","volume":"12","author":"W Yang","year":"2023","unstructured":"Yang W, Mixich L, Boonstra E, Cabral H. Polymer-based mRNA delivery strategies for advanced therapies. Adv Healthc Mater. 2023;12(15):2202688. https:\/\/doi.org\/10.1002\/adhm.202202688.","journal-title":"Adv Healthc Mater"},{"issue":"02","key":"791_CR160","doi-asserted-by":"publisher","first-page":"101","DOI":"10.18609\/nai.2024.015","volume":"01","author":"J Zhai","year":"2024","unstructured":"Zhai J, Cote T, Chen Y. Challenges and advances of the stability of mRNA delivery therapeutics. Nucleic Acid Insights. 2024;01(02):101\u201313. https:\/\/doi.org\/10.18609\/nai.2024.015.","journal-title":"Nucleic Acid Insights"},{"issue":"6","key":"791_CR161","doi-asserted-by":"publisher","first-page":"601","DOI":"10.3390\/vaccines13060601","volume":"13","author":"S Oloruntimehin","year":"2025","unstructured":"Oloruntimehin S, Akinyi F, Paul M, Ariyo O. mRNA vaccine technology beyond COVID-19. Vaccines. 2025;13(6):601. https:\/\/doi.org\/10.3390\/vaccines13060601.","journal-title":"Vaccines"},{"issue":"8","key":"791_CR162","doi-asserted-by":"publisher","first-page":"853","DOI":"10.3390\/vaccines13080853","volume":"13","author":"MFH Khan","year":"2025","unstructured":"Khan MFH, Baudin F, Sudalaiyadum Perumal A, Kamen AA. Freeze-drying of mRNA-LNPs vaccines: a review. Vaccines. 2025;13(8):853. https:\/\/doi.org\/10.3390\/vaccines13080853.","journal-title":"Vaccines"},{"issue":"8","key":"791_CR163","doi-asserted-by":"publisher","first-page":"2706","DOI":"10.1080\/21645515.2021.1875761","volume":"17","author":"S Wen","year":"2021","unstructured":"Wen S, Wu Z, Zhong S, Li M, Shu Y. Factors influencing the immunogenicity of influenza vaccines. Hum Vaccin Immunother. 2021;17(8):2706\u201318. https:\/\/doi.org\/10.1080\/21645515.2021.1875761.","journal-title":"Hum Vaccin Immunother"},{"key":"791_CR164","unstructured":"ClinicalTrials.gov. A study to evaluate a modified RNA vaccine against influenza in adults 18 years of age or older. 2025. https:\/\/clinicaltrials.gov\/study\/NCT05540522. Accessed 14 Nov 2025."},{"issue":"4","key":"791_CR165","doi-asserted-by":"publisher","first-page":"383","DOI":"10.3390\/vaccines13040383","volume":"13","author":"A Branche","year":"2025","unstructured":"Branche A, Mulligan MJ, Maniar A, Puente O, Oladipupo I, Crowther G, et al. A phase 1\/2 randomized study to evaluate the safety, tolerability, and immunogenicity of nucleoside-modified messenger RNA influenza vaccines in healthy adults. Vaccines. 2025;13(4):383. https:\/\/doi.org\/10.3390\/vaccines13040383.","journal-title":"Vaccines"},{"key":"791_CR166","unstructured":"ClinicalTrials.gov. A study to learn how safe, tolerable and capable of producing an immune response is, a modified RNA vaccine against pandemic influenza. 2025. https:\/\/clinicaltrials.gov\/study\/NCT06179446. Accessed 14 Nov 2025."},{"key":"791_CR167","unstructured":"Pfizer. Pfizer reiterates commitment to pandemic preparedness. 2024. https:\/\/www.pfizer.com\/news\/announcements\/pfizer-reiterates-commitment-pandemic-preparedness. Accessed 14 Nov 2025."},{"key":"791_CR168","unstructured":"ClinicalTrials.gov. A study to learn about the study vaccine (called self-amplifying ribonucleic acid (RNA)) for the prevention of influenza. 2023. https:\/\/clinicaltrials.gov\/study\/NCT05227001. Accessed 14 Nov 2025."},{"key":"791_CR169","unstructured":"ClinicalTrials.gov. A study to evaluate the safety, tolerability, and immunogenicity of a combined modified RNA vaccine candidate against COVID-19 and influenza. 2024. https:\/\/clinicaltrials.gov\/study\/NCT06178991. Accessed 14 Nov 2025."},{"key":"791_CR170","unstructured":"ClinicalTrials.gov. Safety and immunogenicity study of self-amplifying RNA pandemic influenza vaccine in adults. 2025. https:\/\/clinicaltrials.gov\/study\/NCT06602531?tab=table. Accessed 14 Nov 2025."},{"key":"791_CR171","unstructured":"ClinicalTrials.gov. Safety and immunogenicity first-in-human dose-ranging study of self-amplifying RNA seasonal influenza vaccine in adults. 2025. https:\/\/www.clinicaltrials.gov\/study\/NCT06125691?spons=COVERAGE%5BFullMatch%5DEXPANSION%5BNone%5D(%22Arcturus%20Therapeutics,%20Inc.%22). Accessed 14 Nov 2025."},{"key":"791_CR172","unstructured":"Arcturus. Arcturus therapeutics announces second quarter 2025 financial update and pipeline progress. 2025. https:\/\/ir.arcturusrx.com\/news-releases\/news-release-details\/arcturus-therapeutics-announces-second-quarter-2025-financial. Accessed 14 Nov 2025."},{"key":"791_CR173","unstructured":"ClinicalTrials.gov. Safety and immunogenicity of quadrivalent influenza mRNA vaccine MRT5413 in adult participants18 years of age and older. 2025. https:\/\/clinicaltrials.gov\/study\/NCT05650554. Accessed 14 Nov 2025."},{"key":"791_CR174","unstructured":"ClinicalTrials.gov. Safety and immunogenicity of quadrivalent influenza mRNA vaccine MRT5407 in adult participants18 years of age and older. 2025. https:\/\/clinicaltrials.gov\/study\/NCT05553301?term=AREA%5BBasicSearch%5D(AREA%5BBasicSearch%5D(mrna%20flu))&rank=10. Accessed 14 Nov 2025."},{"key":"791_CR175","unstructured":"ClinicalTrials.gov. Safety and immunogenicity of quadrivalent influenza mRNA vaccine MRT5410 in adult participants 18 years of age and older. 2025. https:\/\/clinicaltrials.gov\/study\/NCT05624606. Accessed 14 Nov 2025."},{"key":"791_CR176","unstructured":"ClinicalTrials.gov. A study on the safety and immunogenicity of hexavalent influenza mRNA vaccine in adult participants 50 years of age and older. 2025. https:\/\/clinicaltrials.gov\/study\/NCT06744205?tab=table. Accessed 14 Nov 2025."},{"key":"791_CR177","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-021-00420-6","author":"S Chivukula","year":"2021","unstructured":"Chivukula S, Plitnik T, Tibbitts T, Karve S, Dias A, Zhang D, et al. Development of multivalent mRNA vaccine candidates for seasonal or pandemic influenza. npj Vaccines. 2021. https:\/\/doi.org\/10.1038\/s41541-021-00420-6.","journal-title":"npj Vaccines"},{"key":"791_CR178","unstructured":"ClinicalTrials.gov. A study of mRNA-1010 seasonal influenza vaccine in adults. 2024. https:\/\/www.clinicaltrials.gov\/study\/NCT05415462. Accessed 14 Nov 2025."},{"key":"791_CR179","unstructured":"ClinicalTrials.gov. A study of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 candidate seasonal influenza vaccines in healthy adults. 2025. https:\/\/clinicaltrials.gov\/study\/NCT05827068?intr=NCT05827068&rank=1. Accessed 14 Nov 2025."},{"key":"791_CR180","unstructured":"ClinicalTrials.gov. A study of mRNA-1018 pandemic influenza candidate vaccines in healthy adults. 2025. https:\/\/www.clinicaltrials.gov\/study\/NCT05972174?term=AREA%5BInterventionSearch%5D(mRNA-1018)&rank=1. Accessed 14 Nov 2025."},{"key":"791_CR181","unstructured":"ModernaTX I. mRNA-1020-P101 amendment 1. 2022. https:\/\/cdn.clinicaltrials.gov\/large-docs\/89\/NCT05333289\/Prot_000.pdf. Accessed 14 Nov 2025."},{"key":"791_CR182","unstructured":"ClinicalTrials.gov. A study of mRNA-1020 and mRNA-1030 seasonal influenza vaccines in healthy adults. 2024. https:\/\/clinicaltrials.gov\/study\/NCT05333289?intr=NCT05333289&rank=1. Accessed 14 Nov 2025."},{"key":"791_CR183","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-60938-4","author":"AK Rudman Spergel","year":"2025","unstructured":"Rudman Spergel AK, Lee IT, Koslovsky K, Schaefers K, Avanesov A, Logan DK, et al. Immunogenicity and safety of mRNA-based seasonal influenza vaccines encoding hemagglutinin and neuraminidase. Nat Commun. 2025. https:\/\/doi.org\/10.1038\/s41467-025-60938-4.","journal-title":"Nat Commun"},{"key":"791_CR184","unstructured":"ClinicalTrials.gov. Study to investigate the immunogenicity, reactogenicity, and safety of mRNA-1083 vaccine (SARS-CoV-2 [COVID-19] and Influenza) in adults \u2265 50 years of age. 2025. https:\/\/www.clinicaltrials.gov\/study\/NCT06694389?intr=NCT06694389&rank=1. Accessed 14 Nov 2025."},{"issue":"22","key":"791_CR185","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1001\/jama.2025.5646","volume":"333","author":"AK Rudman Spergel","year":"2025","unstructured":"Rudman Spergel AK, Wu I, Deng W, Cardona J, Johnson K, Espinosa-Fernandez I, et al. Immunogenicity and safety of influenza and COVID-19 multicomponent vaccine in adults \u2265 50 years. JAMA. 2025;333(22):1977. https:\/\/doi.org\/10.1001\/jama.2025.5646.","journal-title":"JAMA"},{"key":"791_CR186","unstructured":"ClinicalTrials.gov. A safety, reactogenicity, and immunogenicity study of mRNA-1045 (influenza and respiratory syncytial virus [RSV]) or mRNA-1230 (influenza, RSV, and severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2]) vaccine in adults 50 to 75 years old. 2024. https:\/\/www.clinicaltrials.gov\/study\/NCT05585632?intr=NCT05585632&rank=1&tab=table. Accessed 14 Nov 2025."},{"issue":"25","key":"791_CR187","doi-asserted-by":"publisher","first-page":"3326","DOI":"10.1016\/j.vaccine.2019.04.074","volume":"37","author":"RA Feldman","year":"2019","unstructured":"Feldman RA, Fuhr R, Smolenov I, Ribeiro A, Panther L, Watson M, et al. mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials. Vaccine. 2019;37(25):3326\u201334. https:\/\/doi.org\/10.1016\/j.vaccine.2019.04.074.","journal-title":"Vaccine"},{"key":"791_CR188","unstructured":"ClinicalTrials.gov. Safety, tolerability, and immunogenicity of VAL-506440 in healthy adult subjects. 2022. https:\/\/clinicaltrials.gov\/study\/NCT03076385. Accessed 14 Nov 2025."},{"key":"791_CR189","unstructured":"ClinicalTrials.gov. Safety, tolerability, and immunogenicity of VAL-339851 in healthy adult subjects. 2021. https:\/\/www.clinicaltrials.gov\/study\/NCT03345043?cond=influenza&intr=%20mRNA&page=3&rank=30. Accessed 14 Nov 2025."},{"key":"791_CR190","unstructured":"ClinicalTrials.gov. A study to evaluate the safety and immunogenicity of a single dose of H1ssF-3928 mRNA-LNP in healthy adults. 2025. https:\/\/www.clinicaltrials.gov\/study\/NCT05755620?intr=NCT05755620&rank=1. Accessed 14 Nov 2025."},{"key":"791_CR191","unstructured":"ClinicalTrials.gov. A study to evaluate the safety and immunogenicity of two doses of a novel H5 central antigen mRNA-LNP in healthy adults. 2025. https:\/\/www.clinicaltrials.gov\/study\/NCT07019883?intr=NCT07019883&rank=1. Accessed 14 Nov 2025."},{"key":"791_CR192","unstructured":"ClinicalTrials.gov. A study to evaluate the safety and immunogenicity of two doses of DCVC H1 HA mRNA-LNP in healthy adults. 2025. https:\/\/www.clinicaltrials.gov\/study\/NCT05945485?intr=NCT05945485&rank=1. Accessed 14 Nov 2025."},{"key":"791_CR193","unstructured":"ClinicalTrials.gov. A study to find the dose and assess the immune response and safety of a vaccine against influenza in healthy younger and older adults. 2025. https:\/\/www.clinicaltrials.gov\/study\/NCT06431607?intr=NCT06431607&rank=1. Accessed 14 Nov 2025."},{"key":"791_CR194","unstructured":"GSK. GSK announces positive headline data from phase II seasonal influenza mRNA vaccine programme. 2024. https:\/\/www.gsk.com\/en-gb\/media\/press-releases\/gsk-announces-positive-headline-data-from-phase-ii-seasonal-influenza-mrna-vaccine-programme\/. Accessed 14 Nov 2025."},{"key":"791_CR195","unstructured":"ClinicalTrials.gov. A study to find and confirm the dose and assess safety, reactogenicity and immune response of a vaccine against pandemic H5N1 influenza virus in healthy younger and older adults. 2025. https:\/\/www.clinicaltrials.gov\/study\/NCT06382311?intr=NCT06382311&rank=1. Accessed 14 Nov 2025."},{"key":"791_CR196","unstructured":"ClinicalTrials.gov. Safety, reactogenicity, and immunogenicity study of a self-amplifying MRNA influenza vaccine in healthy adults. 2024. https:\/\/www.clinicaltrials.gov\/study\/NCT06028347?intr=NCT06028347&rank=1. Accessed 14 Nov 2025."},{"issue":"4","key":"791_CR197","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.immuni.2017.09.007","volume":"47","author":"CI Paules","year":"2017","unstructured":"Paules CI, Marston HD, Eisinger RW, Baltimore D, Fauci AS. The pathway to a universal influenza vaccine. Immunity. 2017;47(4):599\u2013603. https:\/\/doi.org\/10.1016\/j.immuni.2017.09.007.","journal-title":"Immunity"}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-026-00791-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40259-026-00791-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-026-00791-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T09:39:13Z","timestamp":1783330753000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40259-026-00791-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,15]]},"references-count":197,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["791"],"URL":"https:\/\/doi.org\/10.1007\/s40259-026-00791-z","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,15]]},"assertion":[{"value":"25 May 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent to Publish"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"The article was conceptualized and organized by W.Z., B.-Z.W., and P.O.; the original draft was written by P.O. and W.Z.; review and editing of the draft were completed by B.-Z.W., W.Z., and P.O. All authors have read and approved the final version of the manuscript.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contribution"}}]}}